drugset / Trial / NCT05549505
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
Timeline
- Start
- 2023-02-15
- Primary completion
- 2024-07-13
- Completion
- 2024-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | vepdegestrant | Other / unclassified | 200 mg | — |